Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical : China tech share weakness offsets strength in energy, healthcare stocks

05/10/2021 | 03:15am EDT

SHANGHAI, May 10 (Reuters) - China stocks wavered with no clear direction on Monday, as losses in tech shares amid Beijing's deepening anti-monopoly war offset gains in energy and healthcare companies.

** The blue-chip CSI300 index fell 0.1% to 4,992.42, but the Shanghai Composite Index rose 0.3% to 3,427.99 points.

** China's Nasdaq-style STAR market dropped 0.8%, while an index tracking the IT sector fell 0.5%, after the internet watchdog on Saturday announced a ban on some mobile app notifications, as regulators ramp up a campaign to rein in internet firms' growing influence.

** "China's anti-monopoly campaign hit investor confidence in tech shares," said Yang Hongxun, analyst at Shandong Shenguang Consulting.

** But healthcare stocks soared, rebounding from last week's drubbing after a U.S. proposal to waive patents for COVID-19 vaccines met with fierce opposition from European governments and pharmaceutical giants. ** Shanghai Fosun Pharmaceutical jumped 10%, the maximum allowed, in Shanghai, after the drugmaker said a subsidiary had agreed to provide a factory to make the COVID-19 vaccine developed by BioNTech in China. ** Energy shares also rose sharply, after a cyber attack shut down a U.S. pipeline operator that provides nearly half of the U.S. east coast's fuel supply, boosting oil and gas futures. (Reporting by Shanghai Newsroom; Editing by Vinay Dwivedi)


ę Reuters 2021
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
08/03SHANGHAI FOSUN PHARMACEUTICAL : Monthly return of equity issuer on movements in ..
PU
08/02SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Wins Regulatory Nod for $770 Millio..
MT
08/02SHANGHAI FOSUN PHARMACEUTICAL : Announcement on the approval from csrc for the p..
PU
07/28SHANGHAI FOSUN PHARMACEUTICAL : An announcement has just been published by the i..
PU
07/19Sisram Medical Seeks $80 Million in Private Placement; Shares Fall 6%
MT
07/19SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement entering into the placing..
PU
07/19SHANGHAI FOSUN PHARMACEUTICAL (GROUP : Ex-dividend day for final dividend
FA
07/14SINOVAC BIOTECH : Fosun-BioNTech COVID-19 vaccine completes China regulator revi..
RE
07/14MARKET CHATTER : BioNTech's COVID-19 Vaccine Advances to Administration Review i..
MT
07/14SHANGHAI FOSUN PHARMACEUTICAL : Poll results of the resolution proposed at the 2..
PU
More news
Financials
Sales 2021 40 184 M 6 220 M 6 220 M
Net income 2021 4 372 M 677 M 677 M
Net Debt 2021 15 917 M 2 464 M 2 464 M
P/E ratio 2021 51,0x
Yield 2021 0,60%
Capitalization 208 B 32 221 M 32 271 M
EV / Sales 2021 5,58x
EV / Sales 2022 4,93x
Nbr of Employees 32 258
Free-Float 58,8%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | 600196 | CNE000000X38 | MarketScreener
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 86,71 CNY
Average target price 57,08 CNY
Spread / Average Target -34,2%
EPS Revisions
Managers and Directors
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman
Sector and Competitors